Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.

Abstract excerpt

Heterozygous familial hypercholesterolemia (HeFH) is a common (early estimates suggested a prevalence of 1 in 500 individuals, but recent studies have indicated that it may be higher) genetic disorder characterized by markedly elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C). HeFH is associated with an elevated risk of premature coronary heart disease, stroke, and peripheral vascular...

Topics

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Biomarkers
• Cholesterol, LDL
• Drug Therapy, Combination
• Genetic Predisposition to Disease
• Heterozygote
• Humans
• Hyperlipoproteinemia Type II
• Hypolipidemic Agents